Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14087988 | 0.87 | TDP1 (0.65) | TDP1CTDSP1CYP4F2CYP4A11MTNR1A | |
| SCHEMBL14046828 | 0.84 | CYP4F2 (0.52) | TDP1CTDSP1CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL30982179 | 0.84 | CYP4F2 (0.52) | TDP1CTDSP1CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL4246764 | 0.84 | CYP4F2 (0.52) | TDP1CTDSP1CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL7117287 | 0.83 | L3MBTL1 (0.45) | TDP1CTDSP1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL7109070 | 0.83 | L3MBTL1 (0.45) | TDP1CTDSP1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL7552940 | 0.83 | LTB4R (0.47) | MTNR1AMTNR1BMAPTCYP1A2CYP2C9 | |
| SCHEMBL7552930 | 0.83 | LTB4R (0.47) | MTNR1AMTNR1BMAPTCYP1A2CYP2C9 | |
| SCHEMBL7557806 | 0.83 | LTB4R (0.47) | MTNR1AMTNR1BMAPTCYP1A2CYP2C9 | |
| SCHEMBL8858322 | 0.82 | MTNR1A (0.45) | TDP1CTDSP1MTNR1AMTNR1BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177616-A1 | Use of chromans | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-28 | — | — | US | disclosed |
| US-6060482-A | SEROTONIN INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-09 | — | — | US | disclosed |
| US-5962513-A | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-05 | — | — | US | disclosed |
| US-5696137-A | TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5696136-A | TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5693653-A | ADMINISTERING AN ANTIDEPRESSANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| US-5585392-A | TREATING OR PREVENTING STROKES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-12-17 | — | — | US | disclosed |
| US-5545643-A | USEFUL FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-13 | — | — | US | disclosed |
| US-5506246-A | Method for treating depression using substituted aminomethyltetralins and their heterocyclic analogues | BAYER AKTIENGESELLSCHAFT (DE) | 1996-04-09 | — | — | US | disclosed |
| US-5468882-A | Serotoninergic agents; central nervous system and psychological disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| US-5371094-A | Azaheterocyclylmethyl-chromans for treating axiety | BAYER AKTIENGESELLSCHAFT (DE) | 1994-12-06 | — | — | US | disclosed |
| US-5326771-A | Piperidylmethyl-substituted chroman derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1994-07-05 | — | — | US | disclosed |
| US-5318988-A | Treating psychoses | BAYER AKTIENGESELLSCHAFT (DE) | 1994-06-07 | — | — | US | disclosed |
| US-5300523-A | Binding serotonin receptors, treating nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-05 | — | — | US | disclosed |
| US-5137901-A | For binding 5-HT 1 receptors; treating central nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177616-A1 | Use of chromans | SNCA, PARK7, COMT | TDP1 120/4885CTDSP1 2015/4885CYP4F2 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.